Monopar Therapeutics (NASDAQ:MNPR) Cut to Sell at Wall Street Zen

Monopar Therapeutics (NASDAQ:MNPR) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Sunday.

Several other analysts have also recently issued reports on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $100.00 price target on shares of Monopar Therapeutics in a report on Monday, March 30th. Piper Sandler set a $105.00 target price on shares of Monopar Therapeutics in a report on Tuesday, June 2nd. BTIG Research reissued a “buy” rating and set a $104.00 target price on shares of Monopar Therapeutics in a report on Monday, February 23rd. HC Wainwright restated a “buy” rating on shares of Monopar Therapeutics in a research report on Tuesday, June 2nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Tuesday, April 21st. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $107.91.

Monopar Therapeutics Trading Up 1.1%

NASDAQ MNPR opened at $59.77 on Friday. The company’s fifty day simple moving average is $58.71 and its 200-day simple moving average is $62.81. Monopar Therapeutics has a 52 week low of $29.18 and a 52 week high of $105.00. The stock has a market cap of $400.46 million, a P/E ratio of -31.46 and a beta of 1.52.

Monopar Therapeutics (NASDAQ:MNPR) last posted its earnings results on Thursday, May 14th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.41. On average, research analysts expect that Monopar Therapeutics will post -2.82 EPS for the current fiscal year.

Hedge Funds Weigh In On Monopar Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Russell Investments Group Ltd. bought a new position in Monopar Therapeutics in the 3rd quarter valued at about $28,000. BNP Paribas Financial Markets grew its position in Monopar Therapeutics by 100.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock valued at $57,000 after buying an additional 349 shares in the last quarter. Sei Investments Co. grew its position in Monopar Therapeutics by 9.5% in the 1st quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock valued at $415,000 after buying an additional 656 shares in the last quarter. Meeder Asset Management Inc. bought a new position in Monopar Therapeutics in the 4th quarter valued at about $65,000. Finally, Caitong International Asset Management Co. Ltd bought a new position in Monopar Therapeutics in the 4th quarter valued at about $86,000. Institutional investors own 1.83% of the company’s stock.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.